Drug Trial Radar · NCT05601882
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Feb 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
920
Actual
Start
Nov 28, 2022
Primary completion
Mar 19, 2024
Study completion Aug 8, 2024
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Nov 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study compares upadacitinib to dupilumab in adolescent and adult participants with moderate to severe AD who have inadequate response to systemic therapies. Adverse events and change in the disease activity will be assessed. Upadacitinib and dupilumab are approved drugs for the treatment of moderate to severe atopic dermatitis (AD). The study is comprised of a 35-day Screening Period, a 16-week treatment Period 1 and a 16-week treatment Period 2. Participants are randomly assigned to 1 of 2 groups called treatment arms to receive upadacitinib Dose A or dupilumab in Period 1. There is a 30-day or 12-week follow-up visit for those on upadacitinib or dupilumab respectively, who will not enter Period 2. In Period 2, participants will receive upadacitinib Dose A or Dose B for 16 weeks, followed by a 30-day follow-up visit. Approximately 880 adolescent and adult participants ages 12 to 64 with moderate to severe AD who are candidates for systemic therapy will be enrolled at up to 330 sites worldwide. There may be higher treatment burden for participants in this trial compared to their standard of care . Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Atopic Dermatitis
Interventions
DupilumabDrug
Dupilumab is administered as a subcutaneous (SC) injection.
UpadacitinibDrug
Extended-release tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving a ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 16Time frame: Baseline and Week 16
Locations
257 sites in 29 countries. Site status is shown where the registry gives one.
Medical Dermatology Specialists /ID# 250212
Phoenix, Arizona
Alliance Dermatology and Mohs Center /ID# 249671
Phoenix, Arizona
Clinical Trials Institute - Northwest Arkansas /ID# 249838
Fayetteville, Arkansas
Arkansas Research Trials /ID# 250722
North Little Rock, Arkansas
Joseph Raoof Md,Inc /Id# 250211
Encino, California
First OC Dermatology /ID# 250686
Fountain Valley, California
Antelope Valley Clinical Trials /ID# 249946
Lancaster, California
Dermatology Research Associates /ID# 249829
Los Angeles, California
University of California Davis Health /ID# 250044
Sacramento, California
Clinical Trials Research Institute /ID# 250213
Thousand Oaks, California
Western States Clinical Res /ID# 250274
Wheat Ridge, Colorado
UConn Health /ID# 253807
Farmington, Connecticut
Yale Center for Clinical Investigation /ID# 254791
New Haven, Connecticut
Clearlyderm Dermatology /ID# 250457
Boca Raton, Florida
Skin Care Research Boca Raton /ID# 250458
Boca Raton, Florida
Olympian Clinical Research /ID# 250453
Clearwater, Florida
Skin Care Research - Hollywood /ID# 250459
Hollywood, Florida
Solutions Through Adv Rch /ID# 250455
Jacksonville, Florida
GSI Clinical Research, LLC /ID# 250768
Margate, Florida
D&H National Research Centers /ID# 250734
Miami, Florida
Florida International Rsrch cr /ID# 249667
Miami, Florida
Wellness Clinical Research - Miami Lakes /ID# 250236
Miami Lakes, Florida
Tory P Sullivan, MD PA /ID# 251136
North Miami Beach, Florida
Precision Clinical Research /ID# 250990
Sunrise, Florida
Advanced Clinical Research Institute /ID# 250460
Tampa, Florida
Metabolic Research Inst /ID# 250046
West Palm Beach, Florida
Treasure Valley Medical Research /ID# 250727
Boise, Idaho
Dawes Fretzin, LLC /ID# 250276
Indianapolis, Indiana
Randall Dermatology of West Lafayette /ID# 250234
West Lafayette, Indiana
Beth Israel Deaconess Medical Center /ID# 251212
Boston, Massachusetts
Beacon Clinical Research, LLC /ID# 251412
Quincy, Massachusetts
Clarkston Dermatology /ID# 250225
Clarkston, Michigan
Henry Ford Medical Center - New Center One /ID# 250228
Detroit, Michigan
Cleaver Dermatology /ID# 250725
Kirksville, Missouri
MediSearch Clinical Trials /ID# 250272
Saint Joseph, Missouri
Duplicate_Allergy, Asthma & Immunology Associates, PC /ID# 250616
Lincoln, Nebraska
Physician Research Collaboration, LLC /ID# 251099
Lincoln, Nebraska
Montefiore Medical Center - Moses Campus /ID# 251214
The Bronx, New York
Derm of Greater Columbus /ID# 250049
Bexley, Ohio
Univ Hosp Cleveland /ID# 250699
Cleveland, Ohio
Showing 40 of 257 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.